Advancing Translational Research Through Precision Drug Delivery and AI-Driven Quantification
As an AAALAC-accredited high-tech enterprise specializing in nonhuman primate (NHP) translational medicine, Prisys Biotech focuses on two core technology pillars that directly address the fundamental challenges in modern drug development:
(1) High-precision drug delivery technologies, and
(2) AI-driven quantitative behavioral analysis platforms.
These capabilities provide researchers with clinically relevant, reproducible, and mechanistically interpretable datasets-supporting programs in CNS disorders, gene and cell therapy, immunology, dermatology, respiratory disease, and pain.
I. Advanced Translational Technology Platforms
1. Real-Time MRI-Guided Drug Delivery (RT-iMRI) and Convection-Enhanced Delivery (CED)
Prisys Biotech offers one of the industry's most clinically translatable CNS delivery platforms, integrating real-time intraoperative MRI navigation with precision microinfusion systems.
Key advantages:
- Sub-millimeter intracranial accuracy: Real-time iMRI enables precise placement and dosing during intracranial administration.
- Effective blood–brain barrier bypass: Direct parenchymal infusion maximizes local bioavailability while reducing systemic exposure.
- Enhanced tissue distribution with CED: Convection-based microinfusion improves volumetric spread of AAVs, cells, and other therapeutic agents.
- Direct clinical relevance: The workflow utilizes clinical-grade systems (e.g., ClearPoint Navigation), bridging preclinical studies with human trials.
- Ideal for: CNS drug developers, gene therapy programs (e.g., AAV9/AAVrh10), cell therapy innovators, and platform-technology researchers requiring robust translational alignment.
2. AI-Driven NHP Behavioral Analysis System (NHP BehaviorAtlas®)
BehaviorAtlas® introduces an objective, quantitative approach to behavioral phenotyping, addressing the limitations of traditional observer-scored systems such as FOB.
Core capabilities:
- 3D motion capture & skeletal reconstruction: Multi-view high-speed imaging and deep learning algorithms track >21 anatomical landmarks to build an accurate 3D skeletal "avatar."
- Markerless acquisition: Eliminates interference from wearable markers, preserving naturalistic behavior.
- Quantitative ethogram generation: Automated classification of ≥14 behavioral categories (e.g., scratching, locomotion, climbing), enabling sensitive longitudinal comparisons.
- Ideal for: CNS pharmacology, safety assessment (including psychedelic-mechanism studies), behavioral toxicity profiling, and pain/itch research requiring unbiased quantification.
3. Nose-to-Brain (N2B) Delivery and Imaging Validation
Prisys Biotech is actively developing and validating nose-to-brain delivery pathways, an emerging strategy for non-invasive CNS targeting.
Technical highlights:
- Alternative route to the CNS: Investigates transport from nasal cavity to olfactory regions and deeper brain structures.
- CT/MRI-guided deposition mapping: Contrast-enhanced imaging (iodinated, barium, and MRI tracers) confirms deposition efficiency at the upper nasal cavity/olfactory mucosa.
- Functional MRI (fMRI) assessment: Preliminary imaging demonstrates CNS functional changes post-nasal administration, consistent with published reports.
- Ideal for: Developers of neurodegenerative, psychiatric, and peptide/biologic therapeutics seeking non-invasive CNS access.
4. Laser Speckle Contrast Imaging (LSCI)–Based Pain Quantification
Prisys Biotech has established a validated Capsaicin-induced dermal vasodilation model, quantified using LSCI as an objective readout of nociceptive and inflammatory responses.
Technical highlights:
- Objective biomarkers: LSCI quantifies changes in dermal blood flow (DBF) and flare area, correlating with pharmacological modulation of pain pathways.
- Model validation: Pretreatment with lidocaine effectively suppresses capsaicin-induced vasodilation, confirming model robustness.
- Ideal for: Companies developing pain therapeutics (including Nav channel inhibitors) or anti-inflammatory dermatology agents.
II. Key NHP Disease Model Portfolio
Integrating these technology platforms with established NHP disease models maximizes translational value.
| Research Area | Recommended Models | Technology-Integrated Advantages | Evidence of Capability |
|---|---|---|---|
| Immunology & Inflammation | Atopic Dermatitis (OVA-induced) and IL-31 Itch Model | BehaviorAtlas® enables 3D quantification of scratching behavior; AD models support monoclonal antibody efficacy testing. | Demonstrated activity evaluation for IL-31 blockers and biologics such as lebrikizumab. |
| Asthma (OVA-induced) | Airway hyperresponsiveness quantified using large-animal pulmonary function systems with ACh-PC50. | Ongoing optimization of sensitization strategies, including Al/Mg adjuvant formulations. | |
| Neuroscience | MCAO Stroke Model | DSA-guided autologous thrombus induction; CT/MRI assessment of infarct evolution and treatment response. | Established a clinically aligned MCAO workflow mimicking stroke onset and thrombolysis paradigms. |
III. Quality and Compliance
Quality and animal welfare are central to all operations at Prisys Biotech.
AAALAC full accreditation: Ensures global-standard animal care and experimental rigor.
Clinical-grade imaging and delivery equipment: Supports reliable, reproducible preclinical data.
Experienced translational research team: Specialized in NHP pharmacology, imaging, and target-organ delivery.
